{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    8,
    10,
    15,
    17,
    31,
    32,
    43
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 0.6,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_6",
        "affectedSection": "Protocol Title / Synopsis",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "The study remains a Phase 3 randomized trial evaluating axicabtagene ciloleucel versus SOC in r/r DLBCL."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_6",
        "affectedSection": "Section 10 - Statistical Considerations",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updates to primary and secondary analysis methods for EFS, ORR, and OS."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_6",
        "reasonText": "To provide updated clinical data and refine statistical analysis plans based on study progression.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_6",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "3.0",
        "beforeText": "Original: 22 May 2017",
        "afterText": "Amendment 6: 14 April 2023",
        "summary": "Updated protocol version and date to reflect Amendment 6."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_6",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "Primary Endpoint",
        "beforeText": "Not explicitly detailed in provided snippet",
        "afterText": "EFS is defined as the time from randomization to the earliest date of disease progression per the Lugano Classification, commencement of new lymphoma therapy, or death from any cause.",
        "summary": "Defined the specific events constituting an EFS event and the use of blinded central review."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_6",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.3.1",
        "beforeText": "Not provided",
        "afterText": "Rituximab + gemcitabine, dexamethasone and cisplatin/carboplatin (R-GDP) suggested dosing",
        "summary": "Added specific suggested dosing regimens for the Standard of Care arm."
      }
    ],
    "summary": {
      "impactCount": 2,
      "reasonCount": 1,
      "changeCount": 3
    }
  }
}